Free Trial
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free STAB Stock Alerts
NASDAQ:STAB

Statera Biopharma (STAB) Stock Price, News & Analysis

Statera Biopharma logo
$0.0001 0.00 (0.00%)
As of 10/13/2026 01:56 PM Eastern
Compare

About Statera Biopharma Stock (NASDAQ:STAB)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$0.0001
▼
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.03
Volume
318 shs
Average Volume
10,641 shs
Market Capitalization
$1.33 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Statera Biopharma, Inc. is a clinical-stage biotechnology company focused on developing therapies that modulate the immune system. Its research efforts have targeted diseases associated with immune dysfunction, including autoimmune conditions, inflammatory disorders, cancer and infectious diseases.

The company has pursued proprietary immune-modulating drug candidates designed to influence the body’s immune response rather than suppress it broadly. Its development programs have included investigational therapies intended for conditions with significant unmet medical needs, although the availability and status of specific programs may change as clinical development progresses.

Statera Biopharma was formerly known as Cytocom, Inc. and adopted its current name in 2021. Publicly available information about its operating activities, commercial reach and leadership is limited.

AI Generated. May Contain Errors.

Receive STAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STAB Stock News Headlines

Statera Biopharma Inc. (STAB)
May 23, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/stab/sec-filings
BNP Paribas Primary New Issues: No STAB Notice - HOMEVI
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294829/0/en/BNP-Paribas-Primary-New-Issues-No-STAB-Notice-HOMEVI.html
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
 |  Banyan Hill Publishing (Ad)
BNP Paribas Primary New Issues: Post-STAB Notice - No Stab NEW IMMO HOLDING
April 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/17/3276309/0/en/BNP-Paribas-Primary-New-Issues-Post-STAB-Notice-No-Stab-NEW-IMMO-HOLDING.html
AZELIS - BNP Paribas Primary New Issues: NO STAB Notice
March 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/05/3250285/0/en/AZELIS-BNP-Paribas-Primary-New-Issues-NO-STAB-Notice.html
BNP Paribas Primary New Issues: POST-STAB Notice: No Stab - Gruppo San Donato S.P.A.
October 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/27/3174373/0/en/BNP-Paribas-Primary-New-Issues-POST-STAB-Notice-No-Stab-Gruppo-San-Donato-S-P-A.html
Statera Biopharma Inc.
October 10, 2025  |  barrons.comhttps://www.barrons.com/market-data/stocks/stab/stock-grader?amp%252525252525253Bmod=searchbar&%25252525253Bmod=searchbar&%25252525252525253Bmod=searchbar
Tivic Health receives two investigational new drug applications from Statera
August 20, 2025  |  msn.comhttps://www.msn.com/en-us/health/general/tivic-health-receives-two-investigational-new-drug-applications-from-statera/ar-AA1KT2Yk
See More Headlines

STAB Stock Analysis - Frequently Asked Questions

Statera Biopharma's stock was trading at $0.0003 at the beginning of the year. Since then, STAB stock has decreased by 66.7% and is now trading at $0.0001.

Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Statera Biopharma investors own include Bollinger Innovations (BINI), Clover Health Investments (CLOV), FuelCell Energy (FCEL), Faraday Future Intelligent Electric (FFAI), Sorrento Therapeutics (SRNE), Exela Technologies (XELA) and Ginkgo Bioworks (DNA).

Company Calendar

Today
10/14/2026
Fiscal Year End
12/31/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:STAB
CIK
1318641
Web
www.staterabiopharma.com
Phone
(888) 613-8802
Fax
716-849-6820
Employees
46
Year Founded
2003

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
13,340,000
Free Float
N/A
Market Cap
$1.33 thousand
Optionable
Not Optionable
Beta
0.05
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:STAB) was last updated on 10/13/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel